Hongri Pharmaceutical was founded in 1996. Under the leadership of the company’s founder, Chairman Yao Xiaoqing, it has developed into a company spanning modern traditional Chinese medicine, chemical synthesis medicine, biotechnology medicine, medical equipment and many other fields. An enterprise group integrating R&D, production, marketing and capital.
The company is a high-tech enterprise jointly recognized by Tianjin Science and Technology Commission, Tianjin Finance Bureau, Tianjin State Taxation Bureau and Tianjin Local Taxation Bureau. It has 13 patents (including 9 invention patents, practical 3 new patents, 1 design patent), 18 invention patents have been accepted, and applications have been applied for scientific research projects by the Ministry of Science and Technology, the National Development and Reform Commission and the Tianjin Municipal Science and Technology Commission, including scientific and technological small and medium-sized enterprise innovation fund projects, major national science and technology projects, and transformation of scientific and technological achievements. Projects, national high-tech industry development investment plans, etc., totaling 18 projects. The company has 8 national new drug certificates and 21 drug approval numbers. The production workshops of all dosage forms have passed GMP certification. At present, the company has obtained 30 registered trademarks, including 1 well-known trademark (Xuebijing) and 2 famous trademarks in Tianjin (Hongri, Chuanwei).
Hongri Pharmaceutical is one of the first GEM companies in the country and the first in Tianjin. It is known as the "Tinmen Entrepreneurship No. 1" and has been continuously listed on the "Forbes" list of China's potential enterprises and ranked among the "2012 Ranked among the top 10 of the Top 20 GEM companies in the 2016 China Listed Company Value Selection, and seventh among the top 20 of the 5th China’s Most Competitive Pharmaceutical Listed Companies. As of August 14, 2013, the total market value of Hongri Pharmaceutical's shares was 15.1 billion, ranking 6th among 38 listed companies in Tianjin, 11th among 100 GEM listed companies, and all 145 pharmaceutical sector listed companies. Ranked 25th in the company, it has become an indomitable little technology giant and was recognized as an “Excellent Little Technology Giant Enterprise” in Tianjin.
The company is mainly engaged in the research, development, production and sales of Chinese patent medicines and Western medicines. Its leading products include Xuebijing Injection, Fasudil Hydrochloride Injection, etc., including its wholly-owned subsidiary Beijing Kangrentang Pharmaceutical Co., Ltd. produces traditional Chinese medicine formula granules. Xuebijing Injection is currently the only national Class II new drug approved by the SFDA in China for the treatment of sepsis and multiple organ dysfunction syndrome. It has a clear therapeutic mechanism and significant therapeutic effects, and has a monopoly position in the market segment; the company owns the The independent intellectual property rights of the drug, with 2 national invention patents; the research and development and industrialization of the drug have received support from the National Development and Reform Commission's "National High-tech Industry Development Investment Plan" and the Ministry of Science and Technology's "Technology-based Small and Medium-sized Enterprises Innovation Fund Project". Won the first prize of Tianjin’s 2006 Excellent Technological Innovation Project, the second prize of the Science and Technology Award issued by the Chinese Society of Integrated Traditional Chinese and Western Medicine, the 2007 Tianjin Patent Excellence Award, and the second prize of the Tianjin 2008 Science and Technology Progress Award; in 2006 In May, it was jointly recognized as a "secret-level national secret technology" by the Ministry of Science and Technology and the State Administration of Secrecy. In 2009, it was selected as a dialectical treatment drug of traditional Chinese medicine by the Ministry of Health's "Influenza A (H1N1) Diagnosis and Treatment Plan (2009 Trial Version 2)".
Fasudil Hydrochloride Injection is a national Class II new drug and the first Rho kinase inhibitor to be marketed in China. The company is the first domestic enterprise to produce APIs and injections of this type, and has a 4-year transition period for new drugs. The R&D and industrialization of this drug received multiple supports from the Ministry of Science and Technology’s “Technology Small and Medium Enterprises Innovation Fund” and the Tianjin Municipal Science and Technology Commission’s “Scientific and Technological Achievements Transformation Project Achievements Recognition Project”; it also won the first prize for Tianjin’s 2007 Excellent Technological Innovation Project. and the second prize of Tianjin Science and Technology Progress Award in 2008.
The company has always adhered to the concept of "pursuing excellent quality and creating a healthy life", and has achieved remarkable results driven by targeted academic marketing. In addition, the company has not forgotten to repay the society. It has donated money and materials many times, which has gained a good reputation and has been widely recognized by all walks of life.
On October 30, 2009, the company was officially listed on the GEM of the Shenzhen Stock Exchange. Seizing this development opportunity, through technological innovation, management innovation, professional academic promotion and fund-raising project construction, The company has comprehensively improved its new drug research and development capabilities, production capacity, operational efficiency, market share and profitability, and achieved good results. In the future, the company will continue to consolidate and develop the overall strength and competitiveness of the enterprise, and repay society and shareholders.